Effect of Thiazolidinediones on Human Bone
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | April 2009 |
| End Date: | July 2011 |
Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study
We will prospectively study 2 groups of diabetic patients treated with pioglitazone or
placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline
and after 26 weeks of treatment, and hBMCs will be isolated from these bone marrow
aspirations. The ability of hBMCs to differentiate into osteoblast and adipocytes lineages
will be compared before and after treatment with pioglitazone and compared to placebo. In
parallel, clinical markers of bone formation and resorption as well as bone mineral density
will be assessed before and after 26 weeks of treatment. Primary endpoint for this study
will be detection of change in number of osteoblasts or adipocytes from cultured hBMCs
between study groups and within each group.
placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline
and after 26 weeks of treatment, and hBMCs will be isolated from these bone marrow
aspirations. The ability of hBMCs to differentiate into osteoblast and adipocytes lineages
will be compared before and after treatment with pioglitazone and compared to placebo. In
parallel, clinical markers of bone formation and resorption as well as bone mineral density
will be assessed before and after 26 weeks of treatment. Primary endpoint for this study
will be detection of change in number of osteoblasts or adipocytes from cultured hBMCs
between study groups and within each group.
E2a. Screening: Prescreening of electronic medical records will be used as much as possible
to reduce screen failure rates. Patients will undergo a full history (with special focus on
inclusion and exclusion criteria), physical exam, and blood draw. Lab work will consist of
CBC, PT, PTT, CMP, HbA1c, PTH, serum beta-HCG in females of childbearing potential and
testosterone in males. We will measure 25(OH) Vitamin D at baseline and completion of the
study.
E2b. Study visits Subjects will be admitted to the Grady GCRC after an overnight fast at the
initial visit and at 26 weeks. Study drug will be dispensed at the initial visit. At the
initial visit and at 26 weeks, subjects will undergo bone marrow aspiration by a skilled and
certified Hematology Oncology fellow, bone densitometry (DXA) of their hip and spine, and a
blood.draw (5mls).
Subjects will be seen in follow-up at the Grady GCRC at 2 weeks and every 4 weeks thereafter
for measurement of body weight, vital signs, and targeted history looking for any side
effects from study drugs.
Study drug will be dispensed to patients at baseline and on monthly follow-up visits
thereafter. To assess compliance, subjects will be instructed to return any unused drug, and
if the subject takes less than 75% of the study medication, the patient will be withdrawn
from the study. Patients will be monitored closely for development of side effects. Glycemic
control will be assessed with HbA1c measurements at baseline, 12 weeks into the study and at
end of study. Home blood sugars, fasting and occasional postprandial blood sugars will be
assessed at each of the study visits.
E2b.2. Bone Marrow Biopsy aspiration: Bone marrow (BM) aspiration will be done by a
hematology and oncology fellow, Dr. Simbo Aduloju, who is certified in doing these
procedures at the Grady GCRC. Subjects will be pre-medicated 30 minutes prior to the
procedure with oral Lorazepam 2mg and Tylenol 500mg for analgesia.The only absolute
contraindication to BM aspirations is the presence of bleeding disorders. During the
screening process, patients will be asked about a history of coagulopathies such as
hemophilia. In addition all patients will have their PT, PTT and platelets checked at
baseline. Under sterile technique and after local anesthesia with 2% lidocaine, 5mls of bone
marrow will be aspirated from the posterior iliac crest using a 16 gauge bone marrow
aspiration needle attached to a 10 ml syringe. The sample will be placed on ice immediately
and transported to the lab of Dr. George Beck. After the procedure, manual pressure will be
applied to the aspiration site for a minimum of 5 minutes to prevent bleeding. Patients
blood pressure will be checked after the procedure and prior to their departure from the
GCRC to ensure absence of hypotension due to lorazepam.
E2b.2.1. Please see section E2c. below for experimental design on procurement of hBMCs from
bone marrow aspirates and determination of osteoblast/adipocyte differentiation capacity
from these hBMCs.
E2b.3. BMD Evaluation: DXA measurements will be performed at the spine and dominant hip
(contralateral hip in the presence of hardware in the dominant hip) using a GE Lunar Prodigy
Instrument (GE medical Systems) at Grady Memorial Hospital. The DXA scanner is calibrated on
a daily basis with the manufacturer's phantom according to manufacturer guidelines.
Short-term root mean square coefficient of variation at our center is 1.1% at the lumbar
spine and 1.5% at the total hip.
E2b.4. Laboratory Assays: Bone formation markers (osteocalcin, procollagen type-I N-terminal
propeptide [P1NP]) and bone resorption markers (β C-terminal telopeptide of type 1 collagen
[β-CTX]) correlate strongly with rates of bone formation and resorption respectively and
provide powerful data as they reflect the average bone turnover globally across all bone
surfaces in the body. The disadvantage of these markers is that they reflect the final state
at the time of sampling and not conditions at any other time point in the experiment.
After an overnight fast, serum will be assayed from subjects between 8 and 9 am to control
for diurnal variation. Blood samples will be collected and processed by nurses at the Grady
GCRC core laboratory. Serum will be sent to the lab of Dr. George Beck and stored at -80◦C.
The following analyses will be done at the end of the study in a single batch for each
marker. Please see table 2 for details of each assay.
to reduce screen failure rates. Patients will undergo a full history (with special focus on
inclusion and exclusion criteria), physical exam, and blood draw. Lab work will consist of
CBC, PT, PTT, CMP, HbA1c, PTH, serum beta-HCG in females of childbearing potential and
testosterone in males. We will measure 25(OH) Vitamin D at baseline and completion of the
study.
E2b. Study visits Subjects will be admitted to the Grady GCRC after an overnight fast at the
initial visit and at 26 weeks. Study drug will be dispensed at the initial visit. At the
initial visit and at 26 weeks, subjects will undergo bone marrow aspiration by a skilled and
certified Hematology Oncology fellow, bone densitometry (DXA) of their hip and spine, and a
blood.draw (5mls).
Subjects will be seen in follow-up at the Grady GCRC at 2 weeks and every 4 weeks thereafter
for measurement of body weight, vital signs, and targeted history looking for any side
effects from study drugs.
Study drug will be dispensed to patients at baseline and on monthly follow-up visits
thereafter. To assess compliance, subjects will be instructed to return any unused drug, and
if the subject takes less than 75% of the study medication, the patient will be withdrawn
from the study. Patients will be monitored closely for development of side effects. Glycemic
control will be assessed with HbA1c measurements at baseline, 12 weeks into the study and at
end of study. Home blood sugars, fasting and occasional postprandial blood sugars will be
assessed at each of the study visits.
E2b.2. Bone Marrow Biopsy aspiration: Bone marrow (BM) aspiration will be done by a
hematology and oncology fellow, Dr. Simbo Aduloju, who is certified in doing these
procedures at the Grady GCRC. Subjects will be pre-medicated 30 minutes prior to the
procedure with oral Lorazepam 2mg and Tylenol 500mg for analgesia.The only absolute
contraindication to BM aspirations is the presence of bleeding disorders. During the
screening process, patients will be asked about a history of coagulopathies such as
hemophilia. In addition all patients will have their PT, PTT and platelets checked at
baseline. Under sterile technique and after local anesthesia with 2% lidocaine, 5mls of bone
marrow will be aspirated from the posterior iliac crest using a 16 gauge bone marrow
aspiration needle attached to a 10 ml syringe. The sample will be placed on ice immediately
and transported to the lab of Dr. George Beck. After the procedure, manual pressure will be
applied to the aspiration site for a minimum of 5 minutes to prevent bleeding. Patients
blood pressure will be checked after the procedure and prior to their departure from the
GCRC to ensure absence of hypotension due to lorazepam.
E2b.2.1. Please see section E2c. below for experimental design on procurement of hBMCs from
bone marrow aspirates and determination of osteoblast/adipocyte differentiation capacity
from these hBMCs.
E2b.3. BMD Evaluation: DXA measurements will be performed at the spine and dominant hip
(contralateral hip in the presence of hardware in the dominant hip) using a GE Lunar Prodigy
Instrument (GE medical Systems) at Grady Memorial Hospital. The DXA scanner is calibrated on
a daily basis with the manufacturer's phantom according to manufacturer guidelines.
Short-term root mean square coefficient of variation at our center is 1.1% at the lumbar
spine and 1.5% at the total hip.
E2b.4. Laboratory Assays: Bone formation markers (osteocalcin, procollagen type-I N-terminal
propeptide [P1NP]) and bone resorption markers (β C-terminal telopeptide of type 1 collagen
[β-CTX]) correlate strongly with rates of bone formation and resorption respectively and
provide powerful data as they reflect the average bone turnover globally across all bone
surfaces in the body. The disadvantage of these markers is that they reflect the final state
at the time of sampling and not conditions at any other time point in the experiment.
After an overnight fast, serum will be assayed from subjects between 8 and 9 am to control
for diurnal variation. Blood samples will be collected and processed by nurses at the Grady
GCRC core laboratory. Serum will be sent to the lab of Dr. George Beck and stored at -80◦C.
The following analyses will be done at the end of the study in a single batch for each
marker. Please see table 2 for details of each assay.
Inclusion Criteria:Subjects with T2DM who are:
- naïve to insulin and TZD therapy
- On diet and lifestyle therapy along with submaximal metformin therapy
- with HbA1c between 7% and 8.0%
- between the ages of 18 and 80 years
- both genders
Exclusion Criteria:
- Contraindications to TZD therapy including congestive heart failure class III or IV,
and/or macular edema
- history of osteoporosis (T score < -2.5 on DXA scanning) or osteoporotic fragility
fracture
- treatment with glucocorticoids within 1 year of study enrollment
- treatment with bisphosphonates,calcitriol, raloxifene, Calcitonin, estrogen
- vitamin D insufficiency, defined as 25(OH)D levels <30 ng/mL or
- hyperparathyroidism
- liver disease (LFTS > 3x upper limits of normal)
- Kidney disease Cr>1.4 in females and Cr>1.5 in males
- smokers (active or within a month from stopping)
- alcohol or drug abuse/dependence
- hypogonadism in males
- mental conditions rendering the subject unable to understand the scope of the study
- female subjects who are pregnant or breast feeding
- chronic obstructive pulmonary disease
- obstructive sleep apnea.
We found this trial at
1
site
Click here to add this to my saved trials
